Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Husain, AN; Chapel, DB; Attanoos, R; Beasley, MB; Brcic, L; Butnor, K; Chirieac, LR; Churg, A; Dacic, S; Galateau-Salle, F; Hiroshima, K; Hung, YP; Klebe, S; Krausz, T; Khoor, A; Litzky, L; Marchevsky, A; Nabeshima, K; Nicholson, AG; Pavlisko, EN; Roden, AC; Roggli, V; Sauter, JL; Schulte, JJ; Sheaff, M; Travis, WD; Tsao, MS; Walts, AE; Colby, TV.
Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Arch Pathol Lab Med. 2024; 148(11):1251-1271 Doi: 10.5858/arpa.2023-0304-RA
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Brcic Luka
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: CONTEXT.—: Mesothelioma is an uncommon tumor that can be difficult to diagnose. OBJECTIVE.—: To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma. DATA SOURCES.—: Pathologists involved in the International Mesothelioma Interest Group and others with expertise in mesothelioma contributed to this update. Reference material includes peer-reviewed publications and textbooks. CONCLUSIONS.—: There was consensus opinion regarding guidelines for (1) histomorphologic diagnosis of mesothelial tumors, including distinction of epithelioid, biphasic, and sarcomatoid mesothelioma; recognition of morphologic variants and patterns; and recognition of common morphologic pitfalls; (2) molecular pathogenesis of mesothelioma; (3) application of immunohistochemical markers to establish mesothelial lineage and distinguish mesothelioma from common morphologic differentials; (4) application of ancillary studies to distinguish benign from malignant mesothelial proliferations, including BAP1 and MTAP immunostains; novel immunomarkers such as Merlin and p53; fluorescence in situ hybridization (FISH) for homozygous deletion of CDKN2A; and novel molecular assays; (5) practical recommendations for routine reporting of mesothelioma, including grading epithelioid mesothelioma and other prognostic parameters; (6) diagnosis of mesothelioma in situ; (7) cytologic diagnosis of mesothelioma, including use of immunostains and molecular assays; and (8) features of nonmalignant peritoneal mesothelial lesions.
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Mesothelioma - diagnosis, genetics, pathology; Biomarkers, Tumor - genetics, metabolism, analysis; Consensus - administration & dosage; Immunohistochemistry - administration & dosage; Diagnosis, Differential - administration & dosage; Mesothelioma, Malignant - diagnosis, pathology, genetics